Oncimmune Holdings PLC Notice of Half Year Results (6751M)
January 25 2021 - 1:00AM
UK Regulatory
TIDMONC
RNS Number : 6751M
Oncimmune Holdings PLC
25 January 2021
25 January 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Notice of Half Year Results
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, will be announcing its half year results
for the six months ended 30 November 2020 on Monday, 15 February
2021.
Adam Hill, Chief Executive Officer, together with Matthew Hall,
Chief Financial Officer, will host a presentation and conference
call for analysts at 11:30am GMT on the day of the results.
For conference call details please contact Alexander Davis of
FTI Consulting at Alexander.Davis@fticonsulting.com or 020 3727
1000.
The management team will also host on Investor Meet Company a
live presentation of the results on Monday, 15 February 2021 at
16:30 GMT.
-- The online presentation will be open to all existing
shareholders and potential new investors.
-- Questions can be submitted before the event via your Investor
Meet Company dashboard or at any time during the live presentation
via the "Ask a Question" function. Responses to the Q&A will be
published at the earliest opportunity on the Investor Meet Company
platform.
-- Investor feedback can also be submitted directly to
management immediately following the event.
Access to Investor Meet Company is free and interested parties
can register to attend the presentation via the following link:
https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor
Attendees who have already registered on the Investor Meet
Company platform to meet the Company will automatically receive an
invitation to the presentation.
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Chris Lee
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Our intimate understanding of the human immune system enables us
to harness its sophisticated response to disease to detect cancer
earlier and to support the development of better therapies. The key
to improving cancer survival is early detection and better
selection for therapy. As a company, we are driven by our passion
to improve cancer survival and to give people extra time.
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. Oncimmune has a diversified and
growing revenue from its portfolio of diagnostic products to detect
early-stage cancer and a contract discovery and development
service-based platform, delivering actionable insights into
therapies to its pharmaceutical and biotech partners .
Oncimmune's ImmunoINSIGHTS platform enables life-science
organisations to optimise drug development and delivery, leading to
more effective targeted as well as safer treatments for patients.
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and
help identify cancer on average four years earlier than standard
clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung,
targets a vast market estimated to grow to GBP3.8bn by 2024. With
over 200,000 tests already performed for patients worldwide and its
use being supported by peer reviewed data in over 12,000 patients,
we are poised to become an integral component of future lung cancer
detection programmes, globally.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, has a discovery research centre in Dortmund,
Germany and a partner representative office in Shanghai, China.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORDZGZMRZDGMZM
(END) Dow Jones Newswires
January 25, 2021 02:00 ET (07:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024